The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections
Open accessAbstract
Antimicrobial resistance has become one of the greatest threats to public health, with rising resistance to carbapenems being a particular concern due to the lack of effective and safe alternative treatment options. Carbapenem-resistant gram-negative bacteria of clinical relevance include the Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter baumannii, and more recently, Stenotrophomonas maltophilia. Colistin and tigecycline have been used as first-line agents for the treatment of infections caused by these pathogens; however, there are uncertainties regarding their efficacy even when used in combination with other agents. More recently, several new agents with activity against certain carbapenem-resistant pathogens have been approved for clinical use or are reaching late-stage clinical development. They include ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam, plazomicin, eravacycline, and cefiderocol. In addition, fosfomycin has been redeveloped in a new intravenous formulation. Data regarding the clinical efficacy of these new agents specific to infections caused by carbapenem-resistant pathogens are slowly emerging and appear to generally favor newer agents over previous best available therapy. As more treatment options become widely available for carbapenem-resistant gram-negative infections, the role of antimicrobial stewardship will become crucial in ensuring appropriate and rationale use of these new agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hidron, A. I., Edwards, J. R., Patel, J., Horan, T. C., Sievert, D. M., Pollock, D. A., Fridkin, S. K., & National Healthcare Safety Network Team and Participating National Healthcare Safety Network Facilities (2008) · Infection Control & Hospital Epidemiology · doi:10.1086/591861 · Cited by 3,724
Acinetobacter baumannii : Emergence of a Successful Pathogen
Peleg, A. Y., Seifert, H., & Paterson, D. L. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-07 · Cited by 3,316
Yong, D., Toleman, M. A., Giske, C. G., Cho, H. S., Sundman, K., Lee, K., & Walsh, T. R. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00774-09 · Cited by 2,519
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases
Munoz-Price, L. S., Poirel, L., Bonomo, R. A., Schwaber, M. J., Daikos, G. L., Cormican, M., Cornaglia, G., Garau, J., Gniadkowski, M., Hayden, M. K., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70190-7 · Cited by 1,627
Aminoglycoside modifying enzymes
Ramirez, M. S., & Tolmasky, M. E. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.08.003 · Cited by 1,464
Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen
Brooke, J. S. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.00019-11 · Cited by 1,434
Weiner, L. M., Webb, A. K., Limbago, B., Dudeck, M. A., Patel, J., Kallen, A. J., Edwards, J. R., & Sievert, D. M. (2016) · Infection Control & Hospital Epidemiology · doi:10.1017/ice.2016.174 · Cited by 1,313
Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology
Poirel, L., & Nordmann, P. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01456.x · Cited by 1,051
The global epidemiology of carbapenemase-producing Enterobacteriaceae
van Duin, D., & Doi, Y. (2017) · Virulence · doi:10.1080/21505594.2016.1222343 · Cited by 1,004
Self-citationEmergence of Oxacillinase-Mediated Resistance to Imipenem in Klebsiella pneumoniae
Poirel, L., Héritier, C., Tolün, V., & Nordmann, P. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.15-22.2004 · Cited by 997
Rapid Detection of Carbapenemase-producing Enterobacteriaceae
Nordmann, P., Poirel, L., & Dortet, L. (2012) · Emerging Infectious Diseases · doi:10.3201/eid1809.120355 · Cited by 761
Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria
Nordmann, P., & Poirel, L. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz824 · Cited by 721
Lauretti, L., Riccio, M. L., Mazzariol, A., Cornaglia, G., Amicosante, G., Fontana, R., & Rossolini, G. M. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.7.1584 · Cited by 677
Bratu, S., Landman, D., Haag, R., Recco, R., Eramo, A., Alam, M., & Quale, J. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.12.1430 · Cited by 573
Deaths Attributable to Carbapenem-Resistant Enterobacteriaceae Infections
Falagas, M. E., Tansarli, G. S., Karageorgopoulos, D. E., & Vardakas, K. Z. (2014) · Emerging Infectious Diseases · doi:10.3201/eid2007.121004 · Cited by 514
Shields, R. K., Nguyen, M. H., Chen, L., Press, E. G., Potoski, B. A., Marini, R. V., Doi, Y., Kreiswirth, B. N., & Clancy, C. J. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00883-17 · Cited by 495
Self-citationvan der Zwaluw, K., de Haan, A., Pluister, G. N., Bootsma, H. J., de Neeling, A. J., & Schouls, L. M. (2015) · PLOS ONE · doi:10.1371/journal.pone.0123690 · Cited by 486
Bradford, P. A., Bratu, S., Urban, C., Visalli, M., Mariano, N., Landman, D., Rahal, J. J., Brooks, S., Cebular, S., & Quale, J. (2004) · Clinical Infectious Diseases · doi:10.1086/421495 · Cited by 485
Wunderink, R. G., Giamarellos-Bourboulis, E. J., Rahav, G., Mathers, A. J., Bassetti, M., Vazquez, J., Cornely, O. A., Solomkin, J., Bhowmick, T., Bishara, J., et al. (2018) · Infectious Diseases and Therapy · doi:10.1007/s40121-018-0214-1 · Cited by 461
Torres, A., Zhong, N., Pachl, J., Timsit, J.-F., Kollef, M., Chen, Z., Song, J., Taylor, D., Laud, P. J., Stone, G. G., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30747-8 · Cited by 441
Osano, E., Arakawa, Y., Wacharotayankun, R., Ohta, M., Horii, T., Ito, H., Yoshimura, F., & Kato, N. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.1.71 · Cited by 440
Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections
Morrill, H. J., Pogue, J. M., Kaye, K. S., & LaPlante, K. L. (2015) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofv050 · Cited by 435
Shields, R. K., Potoski, B. A., Haidar, G., Hao, B., Doi, Y., Chen, L., Press, E. G., Kreiswirth, B. N., Clancy, C. J., & Nguyen, M. H. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw636 · Cited by 430
Self-citationMotsch, J., Murta de Oliveira, C., Stus, V., Köksal, I., Lyulko, O., Boucher, H. W., Kaye, K. S., File, T. M., Brown, M. L., Khan, I., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz530 · Cited by 422
Solomkin, J., Hershberger, E., Miller, B., Popejoy, M., Friedland, I., Steenbergen, J., Yoon, M., Collins, S., Yuan, G., Barie, P. S., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ097 · Cited by 420
Portsmouth, S., van Veenhuyzen, D., Echols, R., Machida, M., Ferreira, J. C. A., Ariyasu, M., Tenke, P., & Nagata, T. D. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30554-1 · Cited by 420
Chang, Y.-T., Lin, C.-Y., Chen, Y.-H., & Hsueh, P.-R. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00893 · Cited by 419
Carmeli, Y., Armstrong, J., Laud, P. J., Newell, P., Stone, G., Wardman, A., & Gasink, L. B. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30004-4 · Cited by 417
Colistin-Resistant Acinetobacter baumannii: Beyond Carbapenem Resistance
Qureshi, Z. A., Hittle, L. E., O'Hara, J. A., Rivera, J. I., Syed, A., Shields, R. K., Pasculle, A. W., Ernst, R. K., & Doi, Y. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ048 · Cited by 395
Self-citationMazuski, J. E., Gasink, L. B., Armstrong, J., Broadhurst, H., Stone, G. G., Rank, D., Llorens, L., Newell, P., & Pachl, J. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw133 · Cited by 393
Wagenlehner, F. M., Umeh, O., Steenbergen, J., Yuan, G., & Darouiche, R. O. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62220-0 · Cited by 388
Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin
Sato, T., & Yamawaki, K. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz826 · Cited by 379
Wagenlehner, F. M., Sobel, J. D., Newell, P., Armstrong, J., Huang, X., Stone, G. G., Yates, K., & Gasink, L. B. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw378 · Cited by 362
Ito, A., Nishikawa, T., Matsumoto, S., Yoshizawa, H., Sato, T., Nakamura, R., Tsuji, M., & Yamano, Y. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01405-16 · Cited by 352
Doi, Y., Wachino, J.-I., & Arakawa, Y. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2016.02.011 · Cited by 341
Self-citationFosfomycin: Mechanism and Resistance
Silver, L. L. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025262 · Cited by 320
Kaye, K. S., Bhowmick, T., Metallidis, S., Bleasdale, S. C., Sagan, O. S., Stus, V., Vazquez, J., Zaitsev, V., Bidair, M., Chorvat, E., et al. (2018) · JAMA · doi:10.1001/jama.2018.0438 · Cited by 314
Haidar, G., Philips, N. J., Shields, R. K., Snyder, D., Cheng, S., Potoski, B. A., Doi, Y., Hao, B., Press, E. G., Cooper, V. S., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix182 · Cited by 277
Self-citationEmergence of Resistance to Imipenem During Therapy for Pseudomonas aeruginosa Infections
Quinn, J. P., Dudek, E. J., DiVincenzo, C. A., Lucks, D. A., & Lerner, S. A. (1986) · Journal of Infectious Diseases · doi:10.1093/infdis/154.2.289 · Cited by 276
Solomkin, J., Evans, D., Slepavicius, A., Lee, P., Marsh, A., Tsai, L., Sutcliffe, J. A., & Horn, P. (2017) · JAMA Surgery · doi:10.1001/jamasurg.2016.4237 · Cited by 276
Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa
Livermore, D. M., Warner, M., & Mushtaq, S. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt178 · Cited by 268
Köhler, T., Michea-Hamzehpour, M., Epp, S. F., & Pechere, J.-C. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.2.424 · Cited by 268
Penwell, W. F., Shapiro, A. B., Giacobbe, R. A., Gu, R.-F., Gao, N., Thresher, J., McLaughlin, R. E., Huband, M. D., DeJonge, B. L. M., Ehmann, D. E., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04808-14 · Cited by 251
Sader, H. S., Farrell, D. J., Flamm, R. K., & Jones, R. N. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.01.007 · Cited by 248
Kohira, N., West, J., Ito, A., Ito-Horiyama, T., Nakamura, R., Sato, T., Rittenhouse, S., Tsuji, M., & Yamano, Y. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01695-15 · Cited by 247
Synthesis and Spectrum of the Neoglycoside ACHN-490
Aggen, J. B., Armstrong, E. S., Goldblum, A. A., Dozzo, P., Linsell, M. S., Gliedt, M. J., Hildebrandt, D. J., Feeney, L. A., Kubo, A., Matias, R. D., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00572-10 · Cited by 243
Sutcliffe, J. A., O'Brien, W., Fyfe, C., & Grossman, T. H. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01288-13 · Cited by 235
Kazmierczak, K. M., Rabine, S., Hackel, M., McLaughlin, R. E., Biedenbach, D. J., Bouchillon, S. K., Sahm, D. F., & Bradford, P. A. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02379-15 · Cited by 220
Once-Daily Plazomicin for Complicated Urinary Tract Infections
Wagenlehner, F. M. E., Cloutier, D. J., Komirenko, A. S., Cebrik, D. S., Krause, K. M., Keepers, T. R., Connolly, L. E., Miller, L. G., Friedland, I., & Dwyer, J. P. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1801467 · Cited by 218
Hackel, M. A., Tsuji, M., Yamano, Y., Echols, R., Karlowsky, J. A., & Sahm, D. F. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00093-17 · Cited by 202
Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?
Tran, T. B., Velkov, T., Nation, R. L., Forrest, A., Tsuji, B. T., Bergen, P. J., & Li, J. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.09.010 · Cited by 200
Haidar, G., Clancy, C. J., Shields, R. K., Hao, B., Cheng, S., & Nguyen, M. H. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02534-16 · Cited by 193
Ito, A., Kohira, N., Bouchillon, S. K., West, J., Rittenhouse, S., Sader, H. S., Rhomberg, P. R., Jones, R. N., Yoshizawa, H., Nakamura, R., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv402 · Cited by 192
Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases
Ito-Horiyama, T., Ishii, Y., Ito, A., Sato, T., Nakamura, R., Fukuhara, N., Tsuji, M., Yamano, Y., Yamaguchi, K., & Tateda, K. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03098-15 · Cited by 187
Stein, G. E., & Babinchak, T. (2013) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.12.004 · Cited by 183
Lucasti, C., Vasile, L., Sandesc, D., Venskutonis, D., McLeroth, P., Lala, M., Rizk, M. L., Brown, M. L., Losada, M. C., Pedley, A., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00633-16 · Cited by 182
Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections
Falcone, M., & Paterson, D. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw239 · Cited by 180
Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae
McKinnell, J. A., Dwyer, J. P., Talbot, G. H., Connolly, L. E., Friedland, I., Smith, A., Jubb, A. M., Serio, A. W., Krause, K. M., & Daikos, G. L. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1807634 · Cited by 180
Castanheira, M., Farrell, S. E., Krause, K. M., Jones, R. N., & Sader, H. S. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01896-13 · Cited by 177
Zusman, O., Altunin, S., Koppel, F., Dishon Benattar, Y., Gedik, H., & Paul, M. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw377 · Cited by 169
Sims, M., Mariyanovski, V., McLeroth, P., Akers, W., Lee, Y.-C., Brown, M. L., Du, J., Pedley, A., Kartsonis, N. A., & Paschke, A. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx139 · Cited by 166
Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic
Grossman, T. H., Starosta, A. L., Fyfe, C., O'Brien, W., Rothstein, D. M., Mikolajka, A., Wilson, D. N., & Sutcliffe, J. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06187-11 · Cited by 162
Kaye, K. S., Rice, L. B., Dane, A. L., Stus, V. P., Sagan, O., Fedosiuk, E., Das, A., Skarinsky, D., Eckburg, P. B., & Ellis‐Grosse, E. J. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz181 · Cited by 155
Adams‐Haduch, J. M., Paterson, D. L., Sidjabat, H. E., Pasculle, A. W., Potoski, B. A., Muto, C. A., Harrison, L. H., & Doi, Y. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00570-08 · Cited by 145
Self-citationAbdallah, M., Olafisoye, O., Cortes, C. D., Urban, C. M., Landman, D., & Quale, J. M. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04809-14 · Cited by 144
In Vitro and In Vivo Activities of a New Cephalosporin, FR264205, against Pseudomonas aeruginosa
Takeda, S., Nakai, T., Wakai, Y., Ikeda, F., & Hatano, K. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00860-06 · Cited by 140
Lob, S. H., Hackel, M., Kazmierczak, K. M., Young, K., Motyl, M. R., Karlowsky, J. A., & Sahm, D. F. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02209-16 · Cited by 140
Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature
Vardakas, K. Z., Legakis, N. J., Triarides, N. A., & Falagas, M. E. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.02.001 · Cited by 139
Craig, W. A., & Andes, D. R. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01590-12 · Cited by 131
Wang, Y. L., Scipione, M. R., Dubrovskaya, Y., & Papadopoulos, J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01324-13 · Cited by 130
Molecular Epidemiology of Carbapenem-Nonsusceptible Acinetobacter baumannii in the United States
Adams‐Haduch, J. M., Onuoha, E. O., Bogdanovich, T., Tian, G., Marschall, J., Urban, C. M., Spellberg, B. J., Rhee, D., Halstead, D. C., Pasculle, A. W., et al. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00619-11 · Cited by 127
Self-citationXiao, X.-Y., Hunt, D. K., Zhou, J., Clark, R. B., Dunwoody, N., Fyfe, C., Grossman, T. H., O’Brien, W. J., Plamondon, L., Rönn, M., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201465w · Cited by 126
Lolans, K., Queenan, A. M., Bush, K., Sahud, A., & Quinn, J. P. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3538-3540.2005 · Cited by 126
A Concise Synthesis of a β-Lactamase Inhibitor
Mangion, I. K., Ruck, R. T., Rivera, N. R., Huffman, M. A., & Shevlin, M. (2011) · Organic Letters · doi:10.1021/ol202195n · Cited by 125
Falagas, M. E., Skalidis, T., Vardakas, K. Z., Legakis, N. J., & on behalf of the Hellenic Cefiderocol Study Group (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx049 · Cited by 122
Walkty, A. J., Adam, H. J., Baxter, M. R., Denisuik, A. J., Lagacé-Wiens, P. R. S., Karlowsky, J. A., Hoban, D. J., & Zhanel, G. G. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02744-13 · Cited by 116
Banerjee, R., & Humphries, R. M. (2016) · Virulence · doi:10.1080/21505594.2016.1185577 · Cited by 107
Cho, S. Y., Kang, C., Kim, J., Ha, Y. E., Chung, D. R., Lee, N. Y., Peck, K. R., & Song, J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01682-13 · Cited by 105
González-Padilla, M., Torre‐Cisneros, J., Rivera-Espinar, F., Pontes-Moreno, A., López‐Cerero, L., Pascual, Á., Natera, C., Rodriguez, M., Salcedo-Leal, I., Rodríguez-López, F., et al. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku432 · Cited by 104
Lepak, A. J., Zhao, M., VanScoy, B. D., Taylor, D. S., Ellis‐Grosse, E. J., Ambrose, P. G., & Andes, D. R. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00476-17 · Cited by 102
Monogue, M. L., Tsuji, M., Yamano, Y., ECHOLS, R. M., & Nicolau, D. P. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01022-17 · Cited by 101
All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials
McGovern, P. C., Wible, M., El‐Tahtawy, A., Biswas, P., & Meyer, R. D. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.01.020 · Cited by 97
Falagas, M. E., Vardakas, K. Z., Tsiveriotis, K., Triarides, N. A., & Tansarli, G. S. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.01.006 · Cited by 97
Pfaller, M. A., Bassetti, M., Duncan, L. R., & Castanheira, M. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx009 · Cited by 97
A Review of Intravenous Minocycline for Treatment of Multidrug-Resistant Acinetobacter Infections
Ritchie, D. J., & Garavaglia-Wilson, A. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu613 · Cited by 92
Livermore, D. M., & Mushtaq, S. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt118 · Cited by 90
Katsube, T., Wajima, T., Ishibashi, T., Ferreira, J. C. A., & ECHOLS, R. M. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01381-16 · Cited by 88
Wei, C., Ni, W., Cai, X., Zhao, J., & Cui, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152132 · Cited by 84
Ranjan, A. K., Shaik, S., Mondal, A., Nandanwar, N., Hussain, A., Semmler, T., Kumar, N., Tiwari, S. K., Jadhav, S., Wieler, L. H., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01345-16 · Cited by 65
Castanheira, M., Doyle, T. B., Smith, C. J., Mendes, R. E., & Sader, H. S. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz243 · Cited by 61
Torrens, G., Cabot, G., Ocampo-Sosa, A. A., Conejo, M. C., Zamorano, L., Navarro, F., Pascual, Á., Martı́nez-Martı́nez, L., & Oliver, A. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01282-16 · Cited by 56
Shortridge, D., Pfaller, M. A., Castanheira, M., & Flamm, R. K. (2017) · Microbial Drug Resistance · doi:10.1089/mdr.2017.0266 · Cited by 53
Huband, M. D., Castanheira, M., Flamm, R. K., Farrell, D. J., Jones, R. N., & Sader, H. S. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03056-15 · Cited by 34
Keepers, T. R., Gomez, M., Celeri, C., Krause, K. M., Biek, D. P., & Critchley, I. A. (2017) · Infectious Diseases and Therapy · doi:10.1007/s40121-017-0150-5 · Cited by 33
Cited by
Bassetti, M., Echols, R., Matsunaga, Y., Ariyasu, M., Doi, Y., Ferrer, R., Lodise, T. P., Naas, T., Niki, Y., Paterson, D. L., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30796-9 · Cited by 828
Self-citationThe Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update
Reynolds, D., & Kollef, M. (2021) · Drugs · doi:10.1007/s40265-021-01635-6 · Cited by 721
Multidrug-resistant Gram-negative bacterial infections
Macesic, N., Uhlemann, A.-C., & Peleg, A. Y. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02081-6 · Cited by 315
Ma, J., Song, X., Li, M., Yu, Z., Cheng, W., Yu, Z., Zhang, W., Zhang, Y., Shen, A., Sun, H., et al. (2023) · Microbiological Research · doi:10.1016/j.micres.2022.127249 · Cited by 308
Nguyen, M., & Joshi, S. G. (2021) · Journal of Applied Microbiology · doi:10.1111/jam.15130 · Cited by 259
Metadata
- Authors
- Doi, Y.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-11-13
- Volume
- 69
- Issue
- Supplement_7
- Pages
- S565-S575
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2983277151
- Cited by
- 652
- References
- 94
- FWCI
- 20.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.